Boothbay Fund Management’s Transmedics TMDX Stock Holding History

Boothbay Fund Management’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,795	Closed	-$212K	–	2288
2023 Q1	$212K	Buy	+2,795	New	+$193K	﹤0.01%	1711
2020 Q3	–	Sell	-10,985	Closed	-$197K	–	1219
2020 Q2	$197K	Buy	+10,985	New	+$172K	0.01%	800

Other funds holding TMDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCP

Sandhill Capital Partners Buffalo, New York $1.23B AUM 13.7% 1-Year Est. Return

Boothbay Fund Management's TMDX Position: Q2 2023 in Review

Boothbay Fund Management sold out of Transmedics (TMDX) in Q2 2023, closing a stake of 2,795 shares — an estimated $212K sold.

Boothbay Fund Management first reported a position in TMDX in Q2 2020 and held it in 2 quarters. The position peaked at $212K in Q1 2023. 240 funds tracked by Wall St. Rank hold TMDX as of Q2 2023.

Boothbay Fund Management reported no remaining Transmedics position as of Q2 2023 after selling out during the quarter.
Boothbay Fund Management sold 2,795 Transmedics shares in Q2 2023, an estimated $212K.
Boothbay Fund Management first reported a position in Transmedics in Q2 2020 and held it in 2 quarters.
Boothbay Fund Management's Transmedics position peaked at $212K in Q1 2023.
240 funds tracked by Wall St. Rank held Transmedics as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.